Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
Selpercatinib is a first-in-class, highly selective RET kinase inhibitor with CNS activity that has shown efficacy in RET fusion-positive lung and thyroid cancers. RET fusions occur rarely in other tumour types. We aimed to investigate the efficacy and safety of selpercatinib in a diverse group of p...
Saved in:
| Published in | The lancet oncology Vol. 23; no. 10; pp. 1261 - 1273 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
01.10.2022
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Selpercatinib is a first-in-class, highly selective RET kinase inhibitor with CNS activity that has shown efficacy in RET fusion-positive lung and thyroid cancers. RET fusions occur rarely in other tumour types. We aimed to investigate the efficacy and safety of selpercatinib in a diverse group of patients with RET fusion-positive non-lung or thyroid advanced solid tumours (ie, a tumour-agnostic population).
LIBRETTO-001 is an ongoing phase 1/2, single-group, open-label, basket trial of selpercatinib in patients aged 18 years and older (or ≥12 years, where permitted by regulatory authorities) with RET-altered cancers. The trial is being conducted at 89 sites in 16 countries; the tumour-agnostic population was enrolled at 30 sites (outpatient and inpatient medical facilities) across eight countries. A prespecified interim analysis of LIBRETTO-001 was planned to investigate the efficacy and safety of selpercatinib in a tumour-agnostic population of patients with RET fusion-positive advanced solid tumours; the data cutoff date was Sept 24, 2021. Eligible patients had disease progression on or after previous systemic therapies or no satisfactory therapeutic options and an Eastern Cooperative Oncology Group performance status of 0–2. Selpercatinib was orally administered in a continuous 28-day cycle. Patients enrolled in the phase 1 dose-escalation portion received between 20 mg once daily or 20–240 mg twice daily; the phase 2 recommended dose was 160 mg twice daily. The primary endpoint was the objective response rate as determined by the independent review committee. The efficacy-evaluable tumour-agnostic population was defined as patients with RET fusion-positive cancer, other than non-small-cell lung cancer and thyroid cancer, who had at least 6 months of follow-up from the first study dose at the time of data cutoff (all responders at the time of data cutoff were followed up for at least 6 months from the onset of response unless they progressed or died earlier). Safety was analysed in the tumour-agnostic population of patients who had been enrolled and received selpercatinib on or before the data cutoff date. This study is registered with ClinicalTrials.gov (NCT03157128) and is still recruiting participants.
Between Dec 4, 2017, and Aug 4, 2021, 45 patients with RET fusion-positive tumour-agnostic cancers were enrolled from the phase 1 dose-escalation and phase 2 dose-expansion cohorts of the trial. 43 (96%) of 45 patients received a starting dose of selpercatinib at the recommended dose of 160 mg twice daily. Of the two patients who did not, one received a dose of 160 mg twice daily via intra-patient dose escalation (as allowed per protocol for patients enrolled in the phase 1 portion of the study at lower doses) and the other patient's starting dose of 120 mg twice daily was never escalated. Of the 41 efficacy-evaluable patients, the objective response rate as per the independent review committee was 43·9% (95% CI 28·5–60·3; 18 of 41 patients). The most common grade 3 or worse treatment-emergent adverse events were hypertension (ten [22%] of 45 patients), increased alanine aminotransferase (seven [16%]), and increased aspartate aminotransferase (six [13%]). Treatment-emergent serious adverse events occurred in 18 (40%) of 45 patients. No treatment-related deaths occurred.
Selpercatinib showed clinically meaningful activity in the RET fusion-positive tumour-agnostic population, with a safety profile consistent with that observed in other indications. Comprehensive genomic testing that includes RET fusions will be crucial for identifying patients who might benefit from selpercatinib.
Loxo Oncology. |
|---|---|
| AbstractList | Selpercatinib is a first-in-class, highly selective RET kinase inhibitor with CNS activity that has shown efficacy in RET fusion-positive lung and thyroid cancers. RET fusions occur rarely in other tumour types. We aimed to investigate the efficacy and safety of selpercatinib in a diverse group of patients with RET fusion-positive non-lung or thyroid advanced solid tumours (ie, a tumour-agnostic population).
LIBRETTO-001 is an ongoing phase 1/2, single-group, open-label, basket trial of selpercatinib in patients aged 18 years and older (or ≥12 years, where permitted by regulatory authorities) with RET-altered cancers. The trial is being conducted at 89 sites in 16 countries; the tumour-agnostic population was enrolled at 30 sites (outpatient and inpatient medical facilities) across eight countries. A prespecified interim analysis of LIBRETTO-001 was planned to investigate the efficacy and safety of selpercatinib in a tumour-agnostic population of patients with RET fusion-positive advanced solid tumours; the data cutoff date was Sept 24, 2021. Eligible patients had disease progression on or after previous systemic therapies or no satisfactory therapeutic options and an Eastern Cooperative Oncology Group performance status of 0–2. Selpercatinib was orally administered in a continuous 28-day cycle. Patients enrolled in the phase 1 dose-escalation portion received between 20 mg once daily or 20–240 mg twice daily; the phase 2 recommended dose was 160 mg twice daily. The primary endpoint was the objective response rate as determined by the independent review committee. The efficacy-evaluable tumour-agnostic population was defined as patients with RET fusion-positive cancer, other than non-small-cell lung cancer and thyroid cancer, who had at least 6 months of follow-up from the first study dose at the time of data cutoff (all responders at the time of data cutoff were followed up for at least 6 months from the onset of response unless they progressed or died earlier). Safety was analysed in the tumour-agnostic population of patients who had been enrolled and received selpercatinib on or before the data cutoff date. This study is registered with ClinicalTrials.gov (NCT03157128) and is still recruiting participants.
Between Dec 4, 2017, and Aug 4, 2021, 45 patients with RET fusion-positive tumour-agnostic cancers were enrolled from the phase 1 dose-escalation and phase 2 dose-expansion cohorts of the trial. 43 (96%) of 45 patients received a starting dose of selpercatinib at the recommended dose of 160 mg twice daily. Of the two patients who did not, one received a dose of 160 mg twice daily via intra-patient dose escalation (as allowed per protocol for patients enrolled in the phase 1 portion of the study at lower doses) and the other patient's starting dose of 120 mg twice daily was never escalated. Of the 41 efficacy-evaluable patients, the objective response rate as per the independent review committee was 43·9% (95% CI 28·5–60·3; 18 of 41 patients). The most common grade 3 or worse treatment-emergent adverse events were hypertension (ten [22%] of 45 patients), increased alanine aminotransferase (seven [16%]), and increased aspartate aminotransferase (six [13%]). Treatment-emergent serious adverse events occurred in 18 (40%) of 45 patients. No treatment-related deaths occurred.
Selpercatinib showed clinically meaningful activity in the RET fusion-positive tumour-agnostic population, with a safety profile consistent with that observed in other indications. Comprehensive genomic testing that includes RET fusions will be crucial for identifying patients who might benefit from selpercatinib.
Loxo Oncology. SummaryBackgroundSelpercatinib is a first-in-class, highly selective RET kinase inhibitor with CNS activity that has shown efficacy in RET fusion-positive lung and thyroid cancers. RET fusions occur rarely in other tumour types. We aimed to investigate the efficacy and safety of selpercatinib in a diverse group of patients with RET fusion-positive non-lung or thyroid advanced solid tumours (ie, a tumour-agnostic population). MethodsLIBRETTO-001 is an ongoing phase 1/2, single-group, open-label, basket trial of selpercatinib in patients aged 18 years and older (or ≥12 years, where permitted by regulatory authorities) with RET-altered cancers. The trial is being conducted at 89 sites in 16 countries; the tumour-agnostic population was enrolled at 30 sites (outpatient and inpatient medical facilities) across eight countries. A prespecified interim analysis of LIBRETTO-001 was planned to investigate the efficacy and safety of selpercatinib in a tumour-agnostic population of patients with RET fusion-positive advanced solid tumours; the data cutoff date was Sept 24, 2021. Eligible patients had disease progression on or after previous systemic therapies or no satisfactory therapeutic options and an Eastern Cooperative Oncology Group performance status of 0–2. Selpercatinib was orally administered in a continuous 28-day cycle. Patients enrolled in the phase 1 dose-escalation portion received between 20 mg once daily or 20–240 mg twice daily; the phase 2 recommended dose was 160 mg twice daily. The primary endpoint was the objective response rate as determined by the independent review committee. The efficacy-evaluable tumour-agnostic population was defined as patients with RET fusion-positive cancer, other than non-small-cell lung cancer and thyroid cancer, who had at least 6 months of follow-up from the first study dose at the time of data cutoff (all responders at the time of data cutoff were followed up for at least 6 months from the onset of response unless they progressed or died earlier). Safety was analysed in the tumour-agnostic population of patients who had been enrolled and received selpercatinib on or before the data cutoff date. This study is registered with ClinicalTrials.gov ( NCT03157128) and is still recruiting participants. FindingsBetween Dec 4, 2017, and Aug 4, 2021, 45 patients with RET fusion-positive tumour-agnostic cancers were enrolled from the phase 1 dose-escalation and phase 2 dose-expansion cohorts of the trial. 43 (96%) of 45 patients received a starting dose of selpercatinib at the recommended dose of 160 mg twice daily. Of the two patients who did not, one received a dose of 160 mg twice daily via intra-patient dose escalation (as allowed per protocol for patients enrolled in the phase 1 portion of the study at lower doses) and the other patient's starting dose of 120 mg twice daily was never escalated. Of the 41 efficacy-evaluable patients, the objective response rate as per the independent review committee was 43·9% (95% CI 28·5–60·3; 18 of 41 patients). The most common grade 3 or worse treatment-emergent adverse events were hypertension (ten [22%] of 45 patients), increased alanine aminotransferase (seven [16%]), and increased aspartate aminotransferase (six [13%]). Treatment-emergent serious adverse events occurred in 18 (40%) of 45 patients. No treatment-related deaths occurred. InterpretationSelpercatinib showed clinically meaningful activity in the RET fusion-positive tumour-agnostic population, with a safety profile consistent with that observed in other indications. Comprehensive genomic testing that includes RET fusions will be crucial for identifying patients who might benefit from selpercatinib. FundingLoxo Oncology. Summary Background Selpercatinib is a first-in-class, highly selective RET kinase inhibitor with CNS activity that has shown efficacy in RET fusion-positive lung and thyroid cancers. RET fusions occur rarely in other tumour types. We aimed to investigate the efficacy and safety of selpercatinib in a diverse group of patients with RET fusion-positive non-lung or thyroid advanced solid tumours (ie, a tumour-agnostic population). Methods LIBRETTO-001 is an ongoing phase 1/2, single-group, open-label, basket trial of selpercatinib in patients aged 18 years and older (or ≥12 years, where permitted by regulatory authorities) with RET-altered cancers. The trial is being conducted at 89 sites in 16 countries; the tumour-agnostic population was enrolled at 30 sites (outpatient and inpatient medical facilities) across eight countries. A prespecified interim analysis of LIBRETTO-001 was planned to investigate the efficacy and safety of selpercatinib in a tumour-agnostic population of patients with RET fusion-positive advanced solid tumours; the data cutoff date was Sept 24, 2021. Eligible patients had disease progression on or after previous systemic therapies or no satisfactory therapeutic options and an Eastern Cooperative Oncology Group performance status of 0–2. Selpercatinib was orally administered in a continuous 28-day cycle. Patients enrolled in the phase 1 dose-escalation portion received between 20 mg once daily or 20–240 mg twice daily; the phase 2 recommended dose was 160 mg twice daily. The primary endpoint was the objective response rate as determined by the independent review committee. The efficacy-evaluable tumour-agnostic population was defined as patients with RET fusion-positive cancer, other than non-small-cell lung cancer and thyroid cancer, who had at least 6 months of follow-up from the first study dose at the time of data cutoff (all responders at the time of data cutoff were followed up for at least 6 months from the onset of response unless they progressed or died earlier). Safety was analysed in the tumour-agnostic population of patients who had been enrolled and received selpercatinib on or before the data cutoff date. This study is registered with ClinicalTrials.gov (NCT03157128) and is still recruiting participants. Findings Between Dec 4, 2017, and Aug 4, 2021, 45 patients with RET fusion-positive tumour-agnostic cancers were enrolled from the phase 1 dose-escalation and phase 2 dose-expansion cohorts of the trial. 43 (96%) of 45 patients received a starting dose of selpercatinib at the recommended dose of 160 mg twice daily. Of the two patients who did not, one received a dose of 160 mg twice daily via intra-patient dose escalation (as allowed per protocol for patients enrolled in the phase 1 portion of the study at lower doses) and the other patient's starting dose of 120 mg twice daily was never escalated. Of the 41 efficacy-evaluable patients, the objective response rate as per the independent review committee was 43·9% (95% CI 28·5–60·3; 18 of 41 patients). The most common grade 3 or worse treatment-emergent adverse events were hypertension (ten [22%] of 45 patients), increased alanine aminotransferase (seven [16%]), and increased aspartate aminotransferase (six [13%]). Treatment-emergent serious adverse events occurred in 18 (40%) of 45 patients. No treatment-related deaths occurred. Interpretation Selpercatinib showed clinically meaningful activity in the RET fusion-positive tumour-agnostic population, with a safety profile consistent with that observed in other indications. Comprehensive genomic testing that includes RET fusions will be crucial for identifying patients who might benefit from selpercatinib. Funding Loxo Oncology. Selpercatinib is a first-in-class, highly selective RET kinase inhibitor with CNS activity that has shown efficacy in RET fusion-positive lung and thyroid cancers. RET fusions occur rarely in other tumour types. We aimed to investigate the efficacy and safety of selpercatinib in a diverse group of patients with RET fusion-positive non-lung or thyroid advanced solid tumours (ie, a tumour-agnostic population).BACKGROUNDSelpercatinib is a first-in-class, highly selective RET kinase inhibitor with CNS activity that has shown efficacy in RET fusion-positive lung and thyroid cancers. RET fusions occur rarely in other tumour types. We aimed to investigate the efficacy and safety of selpercatinib in a diverse group of patients with RET fusion-positive non-lung or thyroid advanced solid tumours (ie, a tumour-agnostic population).LIBRETTO-001 is an ongoing phase 1/2, single-group, open-label, basket trial of selpercatinib in patients aged 18 years and older (or ≥12 years, where permitted by regulatory authorities) with RET-altered cancers. The trial is being conducted at 89 sites in 16 countries; the tumour-agnostic population was enrolled at 30 sites (outpatient and inpatient medical facilities) across eight countries. A prespecified interim analysis of LIBRETTO-001 was planned to investigate the efficacy and safety of selpercatinib in a tumour-agnostic population of patients with RET fusion-positive advanced solid tumours; the data cutoff date was Sept 24, 2021. Eligible patients had disease progression on or after previous systemic therapies or no satisfactory therapeutic options and an Eastern Cooperative Oncology Group performance status of 0-2. Selpercatinib was orally administered in a continuous 28-day cycle. Patients enrolled in the phase 1 dose-escalation portion received between 20 mg once daily or 20-240 mg twice daily; the phase 2 recommended dose was 160 mg twice daily. The primary endpoint was the objective response rate as determined by the independent review committee. The efficacy-evaluable tumour-agnostic population was defined as patients with RET fusion-positive cancer, other than non-small-cell lung cancer and thyroid cancer, who had at least 6 months of follow-up from the first study dose at the time of data cutoff (all responders at the time of data cutoff were followed up for at least 6 months from the onset of response unless they progressed or died earlier). Safety was analysed in the tumour-agnostic population of patients who had been enrolled and received selpercatinib on or before the data cutoff date. This study is registered with ClinicalTrials.gov (NCT03157128) and is still recruiting participants.METHODSLIBRETTO-001 is an ongoing phase 1/2, single-group, open-label, basket trial of selpercatinib in patients aged 18 years and older (or ≥12 years, where permitted by regulatory authorities) with RET-altered cancers. The trial is being conducted at 89 sites in 16 countries; the tumour-agnostic population was enrolled at 30 sites (outpatient and inpatient medical facilities) across eight countries. A prespecified interim analysis of LIBRETTO-001 was planned to investigate the efficacy and safety of selpercatinib in a tumour-agnostic population of patients with RET fusion-positive advanced solid tumours; the data cutoff date was Sept 24, 2021. Eligible patients had disease progression on or after previous systemic therapies or no satisfactory therapeutic options and an Eastern Cooperative Oncology Group performance status of 0-2. Selpercatinib was orally administered in a continuous 28-day cycle. Patients enrolled in the phase 1 dose-escalation portion received between 20 mg once daily or 20-240 mg twice daily; the phase 2 recommended dose was 160 mg twice daily. The primary endpoint was the objective response rate as determined by the independent review committee. The efficacy-evaluable tumour-agnostic population was defined as patients with RET fusion-positive cancer, other than non-small-cell lung cancer and thyroid cancer, who had at least 6 months of follow-up from the first study dose at the time of data cutoff (all responders at the time of data cutoff were followed up for at least 6 months from the onset of response unless they progressed or died earlier). Safety was analysed in the tumour-agnostic population of patients who had been enrolled and received selpercatinib on or before the data cutoff date. This study is registered with ClinicalTrials.gov (NCT03157128) and is still recruiting participants.Between Dec 4, 2017, and Aug 4, 2021, 45 patients with RET fusion-positive tumour-agnostic cancers were enrolled from the phase 1 dose-escalation and phase 2 dose-expansion cohorts of the trial. 43 (96%) of 45 patients received a starting dose of selpercatinib at the recommended dose of 160 mg twice daily. Of the two patients who did not, one received a dose of 160 mg twice daily via intra-patient dose escalation (as allowed per protocol for patients enrolled in the phase 1 portion of the study at lower doses) and the other patient's starting dose of 120 mg twice daily was never escalated. Of the 41 efficacy-evaluable patients, the objective response rate as per the independent review committee was 43·9% (95% CI 28·5-60·3; 18 of 41 patients). The most common grade 3 or worse treatment-emergent adverse events were hypertension (ten [22%] of 45 patients), increased alanine aminotransferase (seven [16%]), and increased aspartate aminotransferase (six [13%]). Treatment-emergent serious adverse events occurred in 18 (40%) of 45 patients. No treatment-related deaths occurred.FINDINGSBetween Dec 4, 2017, and Aug 4, 2021, 45 patients with RET fusion-positive tumour-agnostic cancers were enrolled from the phase 1 dose-escalation and phase 2 dose-expansion cohorts of the trial. 43 (96%) of 45 patients received a starting dose of selpercatinib at the recommended dose of 160 mg twice daily. Of the two patients who did not, one received a dose of 160 mg twice daily via intra-patient dose escalation (as allowed per protocol for patients enrolled in the phase 1 portion of the study at lower doses) and the other patient's starting dose of 120 mg twice daily was never escalated. Of the 41 efficacy-evaluable patients, the objective response rate as per the independent review committee was 43·9% (95% CI 28·5-60·3; 18 of 41 patients). The most common grade 3 or worse treatment-emergent adverse events were hypertension (ten [22%] of 45 patients), increased alanine aminotransferase (seven [16%]), and increased aspartate aminotransferase (six [13%]). Treatment-emergent serious adverse events occurred in 18 (40%) of 45 patients. No treatment-related deaths occurred.Selpercatinib showed clinically meaningful activity in the RET fusion-positive tumour-agnostic population, with a safety profile consistent with that observed in other indications. Comprehensive genomic testing that includes RET fusions will be crucial for identifying patients who might benefit from selpercatinib.INTERPRETATIONSelpercatinib showed clinically meaningful activity in the RET fusion-positive tumour-agnostic population, with a safety profile consistent with that observed in other indications. Comprehensive genomic testing that includes RET fusions will be crucial for identifying patients who might benefit from selpercatinib.Loxo Oncology.FUNDINGLoxo Oncology. |
| Author | Ohe, Yuichiro Weiss, Jared Wolf, Jürgen Szymczak, Sylwia Drilon, Alexander Konda, Bhavana Kang, Hyunseok Sullivan, Loretta Wright, Jennifer Takeda, Masayuki Soldatenkova, Victoria Subbiah, Vivek Spira, Alexander Khan, Saad Ohashi, Kadoaki |
| Author_xml | – sequence: 1 givenname: Vivek surname: Subbiah fullname: Subbiah, Vivek email: vsubbiah@mdanderson.org organization: Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA – sequence: 2 givenname: Jürgen surname: Wolf fullname: Wolf, Jürgen organization: Department of Internal Medicine, Centre for Integrated Oncology, University Hospital Cologne, Cologne, Germany – sequence: 3 givenname: Bhavana surname: Konda fullname: Konda, Bhavana organization: Division of Medical Oncology, Department of Internal Medicine, Ohio State University Comprehensive Cancer Center, Columbus, OH, USA – sequence: 4 givenname: Hyunseok surname: Kang fullname: Kang, Hyunseok organization: Department of Medicine, University of California, San Francisco, CA, USA – sequence: 5 givenname: Alexander surname: Spira fullname: Spira, Alexander organization: Department of Medical Oncology, Virginia Cancer Specialists, US Oncology Research, Fairfax, VA, USA – sequence: 6 givenname: Jared surname: Weiss fullname: Weiss, Jared organization: Division of Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina Chapel Hill, NC, USA – sequence: 7 givenname: Masayuki surname: Takeda fullname: Takeda, Masayuki organization: Department of Medical Oncology, Kindai University Hospital, Osaka, Japan – sequence: 8 givenname: Yuichiro surname: Ohe fullname: Ohe, Yuichiro organization: Department of Thoracic Oncology, National Cancer Centre Hospital, Tokyo, Japan – sequence: 9 givenname: Saad surname: Khan fullname: Khan, Saad organization: Department of Medical Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA – sequence: 10 givenname: Kadoaki surname: Ohashi fullname: Ohashi, Kadoaki organization: Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan – sequence: 11 givenname: Victoria surname: Soldatenkova fullname: Soldatenkova, Victoria organization: Eli Lilly and Company, Indianapolis, IN, USA – sequence: 12 givenname: Sylwia surname: Szymczak fullname: Szymczak, Sylwia organization: Eli Lilly Polska, Warsaw, Poland – sequence: 13 givenname: Loretta surname: Sullivan fullname: Sullivan, Loretta organization: Eli Lilly and Company, Indianapolis, IN, USA – sequence: 14 givenname: Jennifer surname: Wright fullname: Wright, Jennifer organization: Eli Lilly and Company, Indianapolis, IN, USA – sequence: 15 givenname: Alexander surname: Drilon fullname: Drilon, Alexander organization: Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36108661$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkt9u0zAUxiM0xP7AI4AscdNJC7OdOEmHYIJpwKRKk6BcW45z0npz7WA7nfp2PBpO202jEhpXtpPv_Pz5nO8w2TPWQJK8JvgdwaQ4_UHyEqcU52xE6THGLCcpeZYcxM95yvKq2lvvN5L95ND7G4xJSTB7kexnBcFVUZCD5Pe0X9jepWJmrA9KImhbJYVcIWEa5EULYYVsizzoDpwUQRlVI2VQF7dggkd3KszR98spanuvrEk761VQS0DeatWgsOZ7ZMMcHApzYZDuzQzZ4bBy9pFkNLn6HEHT6zQ6PT5DAnVz4QGRU3qCbAcm1aIGfYJq4W8hoOCU0C-T563QHl5t16Pk55fL6cW3dHL99eri0ySVBWYhzdpsTFgFDKqGCFpnuaxzgUVZ1RjjtikoKVs5xpLWosSZzApBsjGLzaTVmDGcHSXnG27X1wtoZHy7E5p3Ti2EW3ErFP_7j1FzPrNLTkiJaUbySBhtCc7-6sEHvlBegtbCgO09pyVheZ5hWkXp2x3pTeyQie8bVBWhJCtpVL15bOnBy_10o-D9RiCd9d5By6UKcW52cKg0J5gPWeLrLPEhKJxSvs4SH6rZTvX9BU_VbTsFcRxLBY57GaMioVEOZOCNVU8SPu4QpI65k0Lfwgr8Qy8I97FoAxkYlK4JA-DDvwH_YeAPaLUJFg |
| CitedBy_id | crossref_primary_10_1016_S1470_2045_22_00556_3 crossref_primary_10_3390_cancers16244252 crossref_primary_10_1016_j_annonc_2024_07_730 crossref_primary_10_1093_carcin_bgae066 crossref_primary_10_1016_j_beem_2023_101794 crossref_primary_10_1007_s10147_024_02579_z crossref_primary_10_1038_s41467_025_57941_0 crossref_primary_10_1089_aipo_2024_0015 crossref_primary_10_1016_j_ejca_2024_114046 crossref_primary_10_1016_j_esmogo_2024_100073 crossref_primary_10_1038_s41523_024_00626_6 crossref_primary_10_1016_j_trecan_2022_11_003 crossref_primary_10_3389_fsurg_2024_1398289 crossref_primary_10_3390_biom14060656 crossref_primary_10_1038_s41573_025_01147_y crossref_primary_10_3390_cancers16050938 crossref_primary_10_3389_fphar_2024_1424980 crossref_primary_10_1200_EDBK_397082 crossref_primary_10_1158_1078_0432_CCR_24_1762 crossref_primary_10_4251_wjgo_v16_i7_2902 crossref_primary_10_1016_j_ctrv_2024_102750 crossref_primary_10_1016_j_heliyon_2024_e35304 crossref_primary_10_1136_bmj_2023_079126 crossref_primary_10_1093_gastro_goae092 crossref_primary_10_1186_s13000_024_01478_1 crossref_primary_10_1097_CAD_0000000000001618 crossref_primary_10_3390_cancers15164146 crossref_primary_10_1158_2159_8290_CD_22_1377 crossref_primary_10_3390_cancers16091690 crossref_primary_10_1200_PO_23_00334 crossref_primary_10_1016_j_esmoop_2024_103444 crossref_primary_10_1200_PO_24_00437 crossref_primary_10_1038_s41698_023_00347_2 crossref_primary_10_1016_j_labinv_2023_100284 crossref_primary_10_1016_j_yao_2025_01_002 crossref_primary_10_1016_j_modpat_2023_100251 crossref_primary_10_1177_17562848231171456 crossref_primary_10_3389_fonc_2024_1427228 crossref_primary_10_3390_cancers15123192 crossref_primary_10_3389_fendo_2023_1145926 crossref_primary_10_1080_14712598_2024_2408754 crossref_primary_10_1016_j_critrevonc_2024_104388 crossref_primary_10_1038_s41591_023_02321_8 crossref_primary_10_1016_j_critrevonc_2023_104080 crossref_primary_10_3390_cancers16081551 crossref_primary_10_1016_j_esmogo_2023_100032 crossref_primary_10_1016_j_livres_2024_11_005 crossref_primary_10_3390_cancers16162862 crossref_primary_10_1016_j_bulcan_2024_11_003 crossref_primary_10_1038_s41698_024_00563_4 crossref_primary_10_1158_1078_0432_CCR_23_0459 crossref_primary_10_1056_NEJMoa2309457 crossref_primary_10_1038_s41571_022_00694_2 crossref_primary_10_1016_S0007_4551_24_00406_5 crossref_primary_10_1016_j_canlet_2025_217540 crossref_primary_10_1177_17588359231189429 crossref_primary_10_1007_s40265_024_02040_5 crossref_primary_10_1016_j_ando_2023_05_003 crossref_primary_10_1016_j_hoc_2024_01_005 crossref_primary_10_21294_1814_4861_2024_23_1_130_141 crossref_primary_10_1007_s11864_023_01153_5 crossref_primary_10_1016_j_celrep_2023_112978 crossref_primary_10_1007_s11523_023_00974_6 crossref_primary_10_3389_fonc_2023_1201599 crossref_primary_10_1016_j_esmoop_2024_104003 crossref_primary_10_1158_2159_8290_CD_23_0467 crossref_primary_10_3390_cimb46060356 crossref_primary_10_1016_j_esmoop_2023_101591 crossref_primary_10_1093_oncolo_oyae206 crossref_primary_10_1016_j_ejca_2023_01_019 crossref_primary_10_1007_s15036_024_3709_5 crossref_primary_10_1038_s41591_022_02160_z crossref_primary_10_1016_j_ejca_2025_115380 crossref_primary_10_1016_j_jmoldx_2025_01_007 crossref_primary_10_3389_fonc_2024_1307458 crossref_primary_10_1177_2632010X231197080 crossref_primary_10_1097_CAD_0000000000001658 crossref_primary_10_1200_JCO_24_01062 crossref_primary_10_3390_pharmaceutics15020664 crossref_primary_10_1002_jso_27717 crossref_primary_10_1016_j_trecan_2023_07_002 crossref_primary_10_1016_j_ccl_2024_08_006 crossref_primary_10_1016_j_esmogo_2024_100130 crossref_primary_10_1007_s00432_024_05954_5 crossref_primary_10_1080_13696998_2024_2317120 crossref_primary_10_1002_hed_27780 crossref_primary_10_1177_17588359241230756 crossref_primary_10_1016_j_jtocrr_2024_100653 crossref_primary_10_1055_s_0043_1770936 crossref_primary_10_3390_cancers16193421 crossref_primary_10_1016_j_ccell_2024_08_010 crossref_primary_10_1055_a_1988_3880 crossref_primary_10_1001_jamasurg_2025_0242 crossref_primary_10_3390_cancers16050879 crossref_primary_10_3390_ijms26062545 crossref_primary_10_1016_j_pharmthera_2023_108344 crossref_primary_10_3390_ijms25074094 crossref_primary_10_3390_cancers16223835 crossref_primary_10_1038_s41571_024_00965_0 crossref_primary_10_1200_PO_24_00297 crossref_primary_10_1007_s10637_024_01485_5 crossref_primary_10_1080_17474124_2024_2416230 crossref_primary_10_1016_j_annonc_2024_04_005 crossref_primary_10_1080_14737140_2024_2387612 crossref_primary_10_1158_1078_0432_CCR_23_0090 crossref_primary_10_3390_cancers15072105 crossref_primary_10_1186_s13045_024_01613_x crossref_primary_10_3390_cancers15225490 crossref_primary_10_3389_fmed_2024_1402902 crossref_primary_10_1016_j_xcrm_2023_101332 crossref_primary_10_3390_curroncol31070266 crossref_primary_10_3390_cells13121071 crossref_primary_10_3390_curroncol30080517 crossref_primary_10_1007_s00761_023_01386_x crossref_primary_10_1158_1078_0432_CCR_22_2438 crossref_primary_10_1007_s12029_024_01149_w crossref_primary_10_1007_s11684_023_0985_y crossref_primary_10_1016_j_lanepe_2024_101170 crossref_primary_10_3389_fonc_2023_1141314 crossref_primary_10_1055_a_1933_8141 crossref_primary_10_1038_s41392_024_01760_0 crossref_primary_10_1038_s41698_023_00378_9 crossref_primary_10_3390_cancers16040739 crossref_primary_10_3390_cancers15092506 crossref_primary_10_1016_j_path_2023_05_002 crossref_primary_10_1038_s41571_023_00770_1 crossref_primary_10_3390_cancers16142529 crossref_primary_10_1016_j_ctrv_2024_102703 crossref_primary_10_1177_17588359241235799 crossref_primary_10_1016_j_annonc_2025_02_010 crossref_primary_10_1200_EDBK_438598 crossref_primary_10_1001_jamanetworkopen_2024_42970 crossref_primary_10_3390_ijms25010543 crossref_primary_10_1016_j_canlet_2025_217444 crossref_primary_10_3390_cancers15174221 crossref_primary_10_1021_acs_jmedchem_4c01424 crossref_primary_10_1200_PO_24_00038 crossref_primary_10_1200_PO_23_00295 crossref_primary_10_1016_j_ejmech_2024_116891 crossref_primary_10_3390_biomedicines12102175 crossref_primary_10_62347_ECED5481 crossref_primary_10_1210_clinem_dgae283 crossref_primary_10_1007_s11864_024_01219_y crossref_primary_10_1016_j_tranon_2023_101744 crossref_primary_10_1016_j_critrevonc_2024_104544 crossref_primary_10_1200_EDBK_438466 crossref_primary_10_1055_s_0044_1787013 crossref_primary_10_1016_j_trecan_2024_01_009 crossref_primary_10_1200_PO_22_00573 crossref_primary_10_3389_fmolb_2024_1448792 crossref_primary_10_1186_s12885_024_12748_y crossref_primary_10_1038_s41698_024_00659_x crossref_primary_10_1158_1078_0432_CCR_22_2509 crossref_primary_10_1146_annurev_cancerbio_061421_012927 crossref_primary_10_1038_s41698_024_00497_x crossref_primary_10_1158_2159_8290_CD_22_1154 crossref_primary_10_3390_ph16040614 crossref_primary_10_1016_j_ctrv_2024_102721 crossref_primary_10_3390_diagnostics14171886 crossref_primary_10_3390_jmp4020012 crossref_primary_10_4103_jhnps_jhnps_10_24 crossref_primary_10_1080_13543784_2025_2473698 crossref_primary_10_3390_cancers16223870 crossref_primary_10_1093_jjco_hyaf012 crossref_primary_10_3390_cancers16010140 crossref_primary_10_1007_s11864_023_01135_7 crossref_primary_10_1093_jjco_hyad074 crossref_primary_10_1002_ijc_34972 crossref_primary_10_1007_s00761_024_01657_1 crossref_primary_10_1016_j_ejca_2022_11_006 crossref_primary_10_1007_s11523_024_01088_3 crossref_primary_10_1016_j_ejca_2024_114000 crossref_primary_10_7759_cureus_54202 crossref_primary_10_1200_OP_23_00830 crossref_primary_10_1200_JCO_24_02514 crossref_primary_10_1007_s15036_023_3214_2 crossref_primary_10_1097_CM9_0000000000003258 crossref_primary_10_1016_j_soc_2023_12_004 crossref_primary_10_1080_14737159_2023_2245752 crossref_primary_10_1016_j_critrevonc_2025_104656 crossref_primary_10_3390_biom13050796 crossref_primary_10_1016_j_soc_2023_12_001 crossref_primary_10_1016_j_ctrv_2024_102747 crossref_primary_10_1016_j_path_2022_09_007 crossref_primary_10_1080_14737140_2023_2267754 crossref_primary_10_1080_14796694_2025_2477974 crossref_primary_10_1016_j_critrevonc_2024_104454 crossref_primary_10_1111_pin_13399 crossref_primary_10_3390_molecules27248839 crossref_primary_10_1016_j_shpsa_2024_02_002 crossref_primary_10_1016_j_esmoop_2024_103647 crossref_primary_10_1200_PO_23_00252 crossref_primary_10_3390_life13102066 crossref_primary_10_1200_EDBK_389574 crossref_primary_10_1016_j_annonc_2022_11_013 crossref_primary_10_1055_a_1917_4870 crossref_primary_10_1093_oncolo_oyad080 crossref_primary_10_1038_s41392_024_02075_w crossref_primary_10_1016_j_trecan_2023_11_005 crossref_primary_10_1016_j_bulcan_2024_06_005 crossref_primary_10_1007_s00761_023_01385_y crossref_primary_10_1177_17588359231177015 crossref_primary_10_1093_gastro_goaf005 crossref_primary_10_1038_s41392_024_02097_4 crossref_primary_10_1016_j_cell_2023_02_040 crossref_primary_10_1016_j_soc_2023_12_026 crossref_primary_10_1158_1535_7163_MCT_22_0629 crossref_primary_10_1177_26345161241238748 crossref_primary_10_1016_j_jpeds_2023_113826 crossref_primary_10_1186_s42047_024_00160_6 crossref_primary_10_3390_cancers15051578 crossref_primary_10_1007_s11096_024_01800_3 crossref_primary_10_23736_S0031_0808_23_05040_1 crossref_primary_10_1080_17474124_2024_2322648 crossref_primary_10_1016_j_amolm_2025_100073 crossref_primary_10_18027_2224_5057_2023_13_3s1_7_17 |
| Cites_doi | 10.1038/nrclinonc.2017.175 10.1016/S1470-2045(19)30856-3 10.1200/JCO.2000.18.17.3101 10.1038/s41591-019-0653-6 10.1371/journal.pone.0165596 10.1158/1078-0432.CCR-21-3597 10.1016/j.annonc.2021.12.014 10.1200/JCO.2007.14.9930 10.1358/dot.2021.57.3.3233363 10.1158/0008-5472.CAN-18-3126 10.1158/2159-8290.CD-21-0450 10.1200/JCO.2007.11.3357 10.1056/NEJMoa1414325 10.1111/his.14082 10.1158/1078-0432.CCR-21-0800 10.1007/s40265-020-01343-7 10.1093/annonc/mdy090 10.1056/NEJMoa1304369 10.1001/jamaoncol.2020.4515 10.1002/hed.24933 10.1016/S1470-2045(21)00578-7 10.1038/nrclinonc.2017.127 10.1056/NEJMoa1011923 10.1056/NEJMoa1714448 10.1016/S0140-6736(12)61900-X 10.1093/carcin/bgz184 10.1093/annonc/mdy137 10.1056/NEJMoa2005651 10.1186/s12967-021-03108-6 10.1016/0197-2456(96)00075-X 10.1186/s40425-018-0342-x 10.3390/genes11040424 10.1056/NEJMoa2005653 10.1038/s41467-022-28848-x 10.1158/1078-0432.CCR-16-1679 |
| ContentType | Journal Article |
| Copyright | 2022 Elsevier Ltd Elsevier Ltd Copyright © 2022 Elsevier Ltd. All rights reserved. 2022. Elsevier Ltd |
| Copyright_xml | – notice: 2022 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2022 Elsevier Ltd. All rights reserved. – notice: 2022. Elsevier Ltd |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 0TZ 3V. 7RV 7TO 7X7 7XB 88E 8AO 8C1 8C2 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1016/S1470-2045(22)00541-1 |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Pharma and Biotech Premium PRO Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Pharma and Biotech Premium PRO MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-5488 |
| EndPage | 1273 |
| ExternalDocumentID | PMC11702314 36108661 10_1016_S1470_2045_22_00541_1 S1470204522005411 1_s2_0_S1470204522005411 |
| Genre | Clinical Trial, Phase II Clinical Trial, Phase I Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GrantInformation | Loxo Oncology. |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: R01 CA251591 – fundername: NCI NIH HHS grantid: U01 CA180964 – fundername: NCI NIH HHS grantid: P30 CA016672 – fundername: NCI NIH HHS grantid: R37 CA259177 – fundername: NCI NIH HHS grantid: R01 CA226864 – fundername: NCI NIH HHS grantid: P30 CA008748 – fundername: NCI NIH HHS grantid: R01 CA273168 – fundername: NCATS NIH HHS grantid: UL1 TR000371 – fundername: NCI NIH HHS grantid: R01 CA242845 |
| GroupedDBID | --- --K --M -RU .1- .55 .FO 0R~ 123 1B1 1P~ 1~5 29L 4.4 457 4CK 4G. 53G 5VS 6PF 7-5 71M 7RV 7X7 88E 8AO 8C1 8C2 8FI 8FJ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABMAC ABMZM ABUWG ABWVN ACGFS ACIEU ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEIPS AEKER AENEX AEUPX AEVXI AFKRA AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA HMCUK HVGLF HZ~ IHE J1W KOM M1P M41 MO0 N9A NAPCQ O-L O9- OC~ OO- OZT P-8 P-9 P2P PCD PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO R2- ROL RPZ SDG SEL SES SPCBC SSH SSZ T5K TLN UKHRP UV1 WOW X7M XBR Z5R 3V. AACTN AFCTW AFKWA AJOXV ALIPV AMFUW RIG SDF ABLVK ABYKQ AHPSJ AJBFU ZA5 AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 0TZ 7TO 7XB 8FK H94 K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c605t-3f39158e5e8d1a2b34cb4a0a78b000fd6217fc90c2ba703c36a13954742895503 |
| IEDL.DBID | 7X7 |
| ISSN | 1470-2045 1474-5488 |
| IngestDate | Thu Aug 21 18:35:01 EDT 2025 Mon Jul 21 11:14:16 EDT 2025 Fri Jul 25 02:58:03 EDT 2025 Wed Feb 19 02:25:37 EST 2025 Thu Apr 24 23:07:47 EDT 2025 Tue Jul 01 01:53:29 EDT 2025 Fri Feb 23 02:36:17 EST 2024 Tue Feb 25 20:02:55 EST 2025 Tue Aug 26 16:33:26 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Language | English |
| License | Copyright © 2022 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c605t-3f39158e5e8d1a2b34cb4a0a78b000fd6217fc90c2ba703c36a13954742895503 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 VSu, JWo, BK, HK, AS, JWe, MT, SK, and AD were responsible for data collection. VSu, JWo, JWe, SK, LS, and AD were responsible for data interpretation. VSu, JWo, SK, LS, and AD were responsible for writing conceptualisation of the manuscript. VSu, YO, SK, and AD were responsible for data curation. VSu, SK, KO, and AD were the principal investigators for this trial. VSu, BK, JWe, YO, SK, KO, VSo, SS, LS, JWr, and AD were responsible for writing, review, and editing of the manuscript. VSo, SS, and JWr were responsible for initial review of acquired data. JWo was responsible for critical revision. LS was responsible for methodology. VSu and AD verified the raw data. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. VSu, SK, and AD were responsible for study design, provision of study materials, enrolment in clinical trials, data analysis, formal analysis, project administration, resources, and writing the original draft. Contributors |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/11702314 |
| PMID | 36108661 |
| PQID | 2718121372 |
| PQPubID | 46089 |
| PageCount | 13 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_11702314 proquest_miscellaneous_2715443028 proquest_journals_2718121372 pubmed_primary_36108661 crossref_citationtrail_10_1016_S1470_2045_22_00541_1 crossref_primary_10_1016_S1470_2045_22_00541_1 elsevier_sciencedirect_doi_10_1016_S1470_2045_22_00541_1 elsevier_clinicalkeyesjournals_1_s2_0_S1470204522005411 elsevier_clinicalkey_doi_10_1016_S1470_2045_22_00541_1 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-10-01 |
| PublicationDateYYYYMMDD | 2022-10-01 |
| PublicationDate_xml | – month: 10 year: 2022 text: 2022-10-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | The lancet oncology |
| PublicationTitleAlternate | Lancet Oncol |
| PublicationYear | 2022 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Drilon, Subbiah, Gautschi (bib18) 2022; 33 Hong, DuBois, Kummar (bib41) 2020; 21 Schemper, Smith (bib24) 1996; 17 Drilon, Oxnard, Tan (bib23) 2020; 383 Pietrantonio, Di Nicolantonio, Schrock (bib10) 2018; 29 Subbiah, Kreitman, Wainberg (bib40) 2022; 33 Mayer, Van Cutsem, Falcone (bib34) 2015; 372 Von Hoff, Ervin, Arena (bib32) 2013; 369 Oaknin, Tinker, Gilbert (bib1) 2020; 6 Drilon, Laetsch, Kummar (bib2) 2018; 378 Saltz, Clarke, Díaz-Rubio (bib31) 2008; 26 Demetri, De Braud, Drilon (bib38) 2022; 28 Cocco, Benhamida, Middha (bib36) 2019; 79 Demetri, Paz-Ares, Farago (bib6) 2018; 29 Drilon, Hu, Lai, Tan (bib8) 2018; 15 (bib42) June 23, 2022 Briasoulis, Kalofonos, Bafaloukos (bib29) 2000; 18 Kohno, Tabata, Nakaoku (bib13) 2020; 41 Friedman, Hainsworth, Kurzrock (bib5) 2022; 12 Subbiah, Gainor, Oxnard (bib16) 2021; 27 Hong, Kim, Koh (bib30) 2018; 40 Su, He, Ma (bib11) 2016; 11 Besse, Drilon, Solomon (bib19) 2021; 39 Davis, Vargas, Rudzinski (bib12) 2020; 76 Markham (bib22) 2020; 80 Von Hoff (bib25) 1998; 4 Wang, Li, Li (bib35) 2021; 19 Wirth, Sherman, Robinson (bib21) 2020; 383 Conroy, Desseigne, Ychou (bib28) 2011; 364 Rubio-Pérez, Hernández, Hernández, Doger, Casado, Moreno (bib3) 2021; 57 Subbiah, Velcheti, Tuch (bib17) 2018; 29 Kato, Subbiah, Marchlik, Elkin, Carter, Kurzrock (bib9) 2017; 23 Wen, Stein, van den Bent (bib39) 2022; 23 Subbiah, Konda, Bauer (bib26) 2021; 81 Durham, Lopez Rodrigo, Picarsic (bib15) 2019; 25 Fuchs, Marshall, Mitchell (bib27) 2007; 25 Santoro, Moccia, Federico, Carlomagno (bib14) 2020; 11 Boyiadzis, Kirkwood, Marshall, Pritchard, Azad, Gulley (bib4) 2018; 6 Schram, Chang, Jonsson, Drilon (bib7) 2017; 14 Sherman, Wirth, Shah (bib20) 2021; 39 Grothey, Van Cutsem, Sobrero (bib33) 2013; 381 Rosen, Won, Zheng (bib37) 2022; 13 Sherman (10.1016/S1470-2045(22)00541-1_bib20) 2021; 39 Fuchs (10.1016/S1470-2045(22)00541-1_bib27) 2007; 25 Schemper (10.1016/S1470-2045(22)00541-1_bib24) 1996; 17 Cocco (10.1016/S1470-2045(22)00541-1_bib36) 2019; 79 Kato (10.1016/S1470-2045(22)00541-1_bib9) 2017; 23 Conroy (10.1016/S1470-2045(22)00541-1_bib28) 2011; 364 Rosen (10.1016/S1470-2045(22)00541-1_bib37) 2022; 13 Hong (10.1016/S1470-2045(22)00541-1_bib41) 2020; 21 Friedman (10.1016/S1470-2045(22)00541-1_bib5) 2022; 12 Davis (10.1016/S1470-2045(22)00541-1_bib12) 2020; 76 Subbiah (10.1016/S1470-2045(22)00541-1_bib26) 2021; 81 Subbiah (10.1016/S1470-2045(22)00541-1_bib16) 2021; 27 Kohno (10.1016/S1470-2045(22)00541-1_bib13) 2020; 41 Wen (10.1016/S1470-2045(22)00541-1_bib39) 2022; 23 Pietrantonio (10.1016/S1470-2045(22)00541-1_bib10) 2018; 29 Grothey (10.1016/S1470-2045(22)00541-1_bib33) 2013; 381 Rubio-Pérez (10.1016/S1470-2045(22)00541-1_bib3) 2021; 57 Subbiah (10.1016/S1470-2045(22)00541-1_bib17) 2018; 29 Boyiadzis (10.1016/S1470-2045(22)00541-1_bib4) 2018; 6 Drilon (10.1016/S1470-2045(22)00541-1_bib2) 2018; 378 Schram (10.1016/S1470-2045(22)00541-1_bib7) 2017; 14 Briasoulis (10.1016/S1470-2045(22)00541-1_bib29) 2000; 18 Durham (10.1016/S1470-2045(22)00541-1_bib15) 2019; 25 Markham (10.1016/S1470-2045(22)00541-1_bib22) 2020; 80 Drilon (10.1016/S1470-2045(22)00541-1_bib18) 2022; 33 Oaknin (10.1016/S1470-2045(22)00541-1_bib1) 2020; 6 Hong (10.1016/S1470-2045(22)00541-1_bib30) 2018; 40 Saltz (10.1016/S1470-2045(22)00541-1_bib31) 2008; 26 Subbiah (10.1016/S1470-2045(22)00541-1_bib40) 2022; 33 Wang (10.1016/S1470-2045(22)00541-1_bib35) 2021; 19 Von Hoff (10.1016/S1470-2045(22)00541-1_bib32) 2013; 369 Drilon (10.1016/S1470-2045(22)00541-1_bib8) 2018; 15 Demetri (10.1016/S1470-2045(22)00541-1_bib38) 2022; 28 Santoro (10.1016/S1470-2045(22)00541-1_bib14) 2020; 11 Besse (10.1016/S1470-2045(22)00541-1_bib19) 2021; 39 Demetri (10.1016/S1470-2045(22)00541-1_bib6) 2018; 29 Drilon (10.1016/S1470-2045(22)00541-1_bib23) 2020; 383 Su (10.1016/S1470-2045(22)00541-1_bib11) 2016; 11 Wirth (10.1016/S1470-2045(22)00541-1_bib21) 2020; 383 Von Hoff (10.1016/S1470-2045(22)00541-1_bib25) 1998; 4 Mayer (10.1016/S1470-2045(22)00541-1_bib34) 2015; 372 36207414 - Nat Rev Clin Oncol. 2022 Dec;19(12):747 36108663 - Lancet Oncol. 2022 Oct;23(10):1235-1237 |
| References_xml | – volume: 27 start-page: 4160 year: 2021 end-page: 4167 ident: bib16 article-title: Intracranial efficacy of selpercatinib in RET fusion-positive non-small cell lung cancers on the LIBRETTO-001 trial publication-title: Clin Cancer Res – volume: 383 start-page: 813 year: 2020 end-page: 824 ident: bib23 article-title: Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer publication-title: N Engl J Med – volume: 79 start-page: 1047 year: 2019 end-page: 1053 ident: bib36 article-title: Colorectal carcinomas containing hypermethylated MLH1 promoter and wild-type BRAF/KRAS are enriched for targetable kinase fusions publication-title: Cancer Res – volume: 12 start-page: 654 year: 2022 end-page: 669 ident: bib5 article-title: Atezolizumab treatment of tumors with high tumor mutational burden from MyPathway, a multicenter, open-label, phase IIa multiple basket study publication-title: Cancer Discov – volume: 381 start-page: 303 year: 2013 end-page: 312 ident: bib33 article-title: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial publication-title: Lancet – volume: 33 start-page: S27 year: 2022 end-page: S70 ident: bib18 article-title: Durability of efficacy and safety with selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC) publication-title: Ann Oncol – volume: 26 start-page: 2013 year: 2008 end-page: 2019 ident: bib31 article-title: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study publication-title: J Clin Oncol – volume: 57 start-page: 187 year: 2021 end-page: 197 ident: bib3 article-title: Dostarlimab for the treatment of endometrium cancer and other solid tumors publication-title: Drugs Today – volume: 29 start-page: 1394 year: 2018 end-page: 1401 ident: bib10 article-title: RET fusions in a small subset of advanced colorectal cancers at risk of being neglected publication-title: Ann Oncol – volume: 29 start-page: 1869 year: 2018 end-page: 1876 ident: bib17 article-title: Selective RET kinase inhibition for patients with RET-altered cancers publication-title: Ann Oncol – volume: 33 start-page: 406 year: 2022 end-page: 415 ident: bib40 article-title: Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study publication-title: Ann Oncol – volume: 41 start-page: 123 year: 2020 end-page: 129 ident: bib13 article-title: REToma: a cancer subtype with a shared driver oncogene publication-title: Carcinogenesis – volume: 23 start-page: 1988 year: 2017 end-page: 1997 ident: bib9 article-title: RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients publication-title: Clin Cancer Res – volume: 14 start-page: 735 year: 2017 end-page: 748 ident: bib7 article-title: Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance publication-title: Nat Rev Clin Oncol – volume: 39 year: 2021 ident: bib19 article-title: Updated overall efficacy and safety of selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC) publication-title: J Clin Oncol – volume: 18 start-page: 3101 year: 2000 end-page: 3107 ident: bib29 article-title: Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study publication-title: J Clin Oncol – volume: 364 start-page: 1817 year: 2011 end-page: 1825 ident: bib28 article-title: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer publication-title: N Engl J Med – volume: 11 year: 2016 ident: bib11 article-title: RET/PTC rearrangements are associated with elevated postoperative TSH levels and multifocal lesions in papillary thyroid cancer without concomitant thyroid benign disease publication-title: PLoS One – volume: 29 start-page: ix173 year: 2018 end-page: ix178 ident: bib6 article-title: Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001 publication-title: Ann Oncol – volume: 25 start-page: 1839 year: 2019 end-page: 1842 ident: bib15 article-title: Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms publication-title: Nat Med – volume: 40 start-page: 55 year: 2018 end-page: 62 ident: bib30 article-title: Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck publication-title: Head Neck – volume: 6 start-page: 1766 year: 2020 end-page: 1772 ident: bib1 article-title: Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial publication-title: JAMA Oncol – volume: 39 year: 2021 ident: bib20 article-title: Selpercatinib efficacy and safety in patients with RET-altered thyroid cancer: a clinical trial update publication-title: Proc Am Soc Clin Oncol – volume: 17 start-page: 343 year: 1996 end-page: 346 ident: bib24 article-title: A note on quantifying follow-up in studies of failure time publication-title: Control Clin Trials – volume: 369 start-page: 1691 year: 2013 end-page: 1703 ident: bib32 article-title: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine publication-title: N Engl J Med – volume: 76 start-page: 1032 year: 2020 end-page: 1041 ident: bib12 article-title: Recurrent RET gene fusions in paediatric spindle mesenchymal neoplasms publication-title: Histopathology – volume: 23 start-page: 53 year: 2022 end-page: 64 ident: bib39 article-title: Dabrafenib plus trametinib in patients with BRAF publication-title: Lancet Oncol – volume: 13 start-page: 1450 year: 2022 end-page: 1458 ident: bib37 article-title: The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers publication-title: Nat Commun – volume: 80 start-page: 1119 year: 2020 end-page: 1124 ident: bib22 article-title: Selpercatinib: first approval publication-title: Drugs – volume: 372 start-page: 1909 year: 2015 end-page: 1919 ident: bib34 article-title: Randomized trial of TAS-102 for refractory metastatic colorectal cancer publication-title: N Engl J Med – volume: 81 year: 2021 ident: bib26 article-title: Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers publication-title: Cancer Res – volume: 19 start-page: 433 year: 2021 ident: bib35 article-title: Comprehensive analysis of oncogenic fusions in mismatch repair deficient colorectal carcinomas by sequential DNA and RNA next generation sequencing publication-title: J Transl Med – volume: 378 start-page: 731 year: 2018 end-page: 739 ident: bib2 article-title: Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children publication-title: N Engl J Med – volume: 6 start-page: 35 year: 2018 ident: bib4 article-title: Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease publication-title: J Immunother Cancer – volume: 11 start-page: 424 year: 2020 ident: bib14 article-title: RET gene fusions in malignancies of the thyroid and other tissues publication-title: Genes – volume: 25 start-page: 4779 year: 2007 end-page: 4786 ident: bib27 article-title: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study publication-title: J Clin Oncol – volume: 4 start-page: 1079 year: 1998 end-page: 1086 ident: bib25 article-title: There are no bad anticancer agents, only bad clinical trial designs—twenty-first Richard and Hinda Rosenthal Foundation Award Lecture publication-title: Clin Cancer Res – volume: 21 start-page: 531 year: 2020 end-page: 540 ident: bib41 article-title: Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials publication-title: Lancet Oncol – year: June 23, 2022 ident: bib42 article-title: FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation – volume: 15 start-page: 151 year: 2018 end-page: 167 ident: bib8 article-title: Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes publication-title: Nat Rev Clin Oncol – volume: 383 start-page: 825 year: 2020 end-page: 835 ident: bib21 article-title: Efficacy of selpercatinib in RET-altered thyroid cancers publication-title: N Engl J Med – volume: 28 start-page: 1302 year: 2022 end-page: 1312 ident: bib38 article-title: Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors publication-title: Clin Cancer Res – volume: 15 start-page: 151 year: 2018 ident: 10.1016/S1470-2045(22)00541-1_bib8 article-title: Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2017.175 – volume: 21 start-page: 531 year: 2020 ident: 10.1016/S1470-2045(22)00541-1_bib41 article-title: Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials publication-title: Lancet Oncol doi: 10.1016/S1470-2045(19)30856-3 – volume: 18 start-page: 3101 year: 2000 ident: 10.1016/S1470-2045(22)00541-1_bib29 article-title: Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study publication-title: J Clin Oncol doi: 10.1200/JCO.2000.18.17.3101 – volume: 25 start-page: 1839 year: 2019 ident: 10.1016/S1470-2045(22)00541-1_bib15 article-title: Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms publication-title: Nat Med doi: 10.1038/s41591-019-0653-6 – volume: 11 year: 2016 ident: 10.1016/S1470-2045(22)00541-1_bib11 article-title: RET/PTC rearrangements are associated with elevated postoperative TSH levels and multifocal lesions in papillary thyroid cancer without concomitant thyroid benign disease publication-title: PLoS One doi: 10.1371/journal.pone.0165596 – volume: 28 start-page: 1302 year: 2022 ident: 10.1016/S1470-2045(22)00541-1_bib38 article-title: Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-21-3597 – volume: 33 start-page: 406 year: 2022 ident: 10.1016/S1470-2045(22)00541-1_bib40 article-title: Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study publication-title: Ann Oncol doi: 10.1016/j.annonc.2021.12.014 – volume: 26 start-page: 2013 year: 2008 ident: 10.1016/S1470-2045(22)00541-1_bib31 article-title: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study publication-title: J Clin Oncol doi: 10.1200/JCO.2007.14.9930 – volume: 57 start-page: 187 year: 2021 ident: 10.1016/S1470-2045(22)00541-1_bib3 article-title: Dostarlimab for the treatment of endometrium cancer and other solid tumors publication-title: Drugs Today doi: 10.1358/dot.2021.57.3.3233363 – volume: 39 issue: suppl year: 2021 ident: 10.1016/S1470-2045(22)00541-1_bib20 article-title: Selpercatinib efficacy and safety in patients with RET-altered thyroid cancer: a clinical trial update publication-title: Proc Am Soc Clin Oncol – volume: 79 start-page: 1047 year: 2019 ident: 10.1016/S1470-2045(22)00541-1_bib36 article-title: Colorectal carcinomas containing hypermethylated MLH1 promoter and wild-type BRAF/KRAS are enriched for targetable kinase fusions publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-18-3126 – volume: 12 start-page: 654 year: 2022 ident: 10.1016/S1470-2045(22)00541-1_bib5 article-title: Atezolizumab treatment of tumors with high tumor mutational burden from MyPathway, a multicenter, open-label, phase IIa multiple basket study publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-21-0450 – volume: 25 start-page: 4779 year: 2007 ident: 10.1016/S1470-2045(22)00541-1_bib27 article-title: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study publication-title: J Clin Oncol doi: 10.1200/JCO.2007.11.3357 – volume: 372 start-page: 1909 year: 2015 ident: 10.1016/S1470-2045(22)00541-1_bib34 article-title: Randomized trial of TAS-102 for refractory metastatic colorectal cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1414325 – volume: 76 start-page: 1032 year: 2020 ident: 10.1016/S1470-2045(22)00541-1_bib12 article-title: Recurrent RET gene fusions in paediatric spindle mesenchymal neoplasms publication-title: Histopathology doi: 10.1111/his.14082 – volume: 27 start-page: 4160 year: 2021 ident: 10.1016/S1470-2045(22)00541-1_bib16 article-title: Intracranial efficacy of selpercatinib in RET fusion-positive non-small cell lung cancers on the LIBRETTO-001 trial publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-21-0800 – volume: 33 start-page: S27 issue: suppl year: 2022 ident: 10.1016/S1470-2045(22)00541-1_bib18 article-title: Durability of efficacy and safety with selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC) publication-title: Ann Oncol – volume: 81 issue: suppl year: 2021 ident: 10.1016/S1470-2045(22)00541-1_bib26 article-title: Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers publication-title: Cancer Res – volume: 80 start-page: 1119 year: 2020 ident: 10.1016/S1470-2045(22)00541-1_bib22 article-title: Selpercatinib: first approval publication-title: Drugs doi: 10.1007/s40265-020-01343-7 – volume: 29 start-page: 1394 year: 2018 ident: 10.1016/S1470-2045(22)00541-1_bib10 article-title: RET fusions in a small subset of advanced colorectal cancers at risk of being neglected publication-title: Ann Oncol doi: 10.1093/annonc/mdy090 – volume: 369 start-page: 1691 year: 2013 ident: 10.1016/S1470-2045(22)00541-1_bib32 article-title: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine publication-title: N Engl J Med doi: 10.1056/NEJMoa1304369 – volume: 6 start-page: 1766 year: 2020 ident: 10.1016/S1470-2045(22)00541-1_bib1 article-title: Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2020.4515 – volume: 40 start-page: 55 year: 2018 ident: 10.1016/S1470-2045(22)00541-1_bib30 article-title: Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck publication-title: Head Neck doi: 10.1002/hed.24933 – volume: 23 start-page: 53 year: 2022 ident: 10.1016/S1470-2045(22)00541-1_bib39 article-title: Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(21)00578-7 – volume: 14 start-page: 735 year: 2017 ident: 10.1016/S1470-2045(22)00541-1_bib7 article-title: Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2017.127 – volume: 364 start-page: 1817 year: 2011 ident: 10.1016/S1470-2045(22)00541-1_bib28 article-title: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1011923 – volume: 378 start-page: 731 year: 2018 ident: 10.1016/S1470-2045(22)00541-1_bib2 article-title: Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children publication-title: N Engl J Med doi: 10.1056/NEJMoa1714448 – volume: 381 start-page: 303 year: 2013 ident: 10.1016/S1470-2045(22)00541-1_bib33 article-title: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(12)61900-X – volume: 39 issue: suppl year: 2021 ident: 10.1016/S1470-2045(22)00541-1_bib19 article-title: Updated overall efficacy and safety of selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC) publication-title: J Clin Oncol – volume: 41 start-page: 123 year: 2020 ident: 10.1016/S1470-2045(22)00541-1_bib13 article-title: REToma: a cancer subtype with a shared driver oncogene publication-title: Carcinogenesis doi: 10.1093/carcin/bgz184 – volume: 29 start-page: 1869 year: 2018 ident: 10.1016/S1470-2045(22)00541-1_bib17 article-title: Selective RET kinase inhibition for patients with RET-altered cancers publication-title: Ann Oncol doi: 10.1093/annonc/mdy137 – volume: 29 start-page: ix173 issue: suppl year: 2018 ident: 10.1016/S1470-2045(22)00541-1_bib6 article-title: Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001 publication-title: Ann Oncol – volume: 383 start-page: 825 year: 2020 ident: 10.1016/S1470-2045(22)00541-1_bib21 article-title: Efficacy of selpercatinib in RET-altered thyroid cancers publication-title: N Engl J Med doi: 10.1056/NEJMoa2005651 – volume: 19 start-page: 433 year: 2021 ident: 10.1016/S1470-2045(22)00541-1_bib35 article-title: Comprehensive analysis of oncogenic fusions in mismatch repair deficient colorectal carcinomas by sequential DNA and RNA next generation sequencing publication-title: J Transl Med doi: 10.1186/s12967-021-03108-6 – volume: 17 start-page: 343 year: 1996 ident: 10.1016/S1470-2045(22)00541-1_bib24 article-title: A note on quantifying follow-up in studies of failure time publication-title: Control Clin Trials doi: 10.1016/0197-2456(96)00075-X – volume: 4 start-page: 1079 year: 1998 ident: 10.1016/S1470-2045(22)00541-1_bib25 article-title: There are no bad anticancer agents, only bad clinical trial designs—twenty-first Richard and Hinda Rosenthal Foundation Award Lecture publication-title: Clin Cancer Res – volume: 6 start-page: 35 year: 2018 ident: 10.1016/S1470-2045(22)00541-1_bib4 article-title: Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease publication-title: J Immunother Cancer doi: 10.1186/s40425-018-0342-x – volume: 11 start-page: 424 year: 2020 ident: 10.1016/S1470-2045(22)00541-1_bib14 article-title: RET gene fusions in malignancies of the thyroid and other tissues publication-title: Genes doi: 10.3390/genes11040424 – volume: 383 start-page: 813 year: 2020 ident: 10.1016/S1470-2045(22)00541-1_bib23 article-title: Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa2005653 – volume: 13 start-page: 1450 year: 2022 ident: 10.1016/S1470-2045(22)00541-1_bib37 article-title: The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers publication-title: Nat Commun doi: 10.1038/s41467-022-28848-x – volume: 23 start-page: 1988 year: 2017 ident: 10.1016/S1470-2045(22)00541-1_bib9 article-title: RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-16-1679 – reference: 36207414 - Nat Rev Clin Oncol. 2022 Dec;19(12):747 – reference: 36108663 - Lancet Oncol. 2022 Oct;23(10):1235-1237 |
| SSID | ssj0017105 |
| Score | 2.7149282 |
| Snippet | Selpercatinib is a first-in-class, highly selective RET kinase inhibitor with CNS activity that has shown efficacy in RET fusion-positive lung and thyroid... SummaryBackgroundSelpercatinib is a first-in-class, highly selective RET kinase inhibitor with CNS activity that has shown efficacy in RET fusion-positive lung... Summary Background Selpercatinib is a first-in-class, highly selective RET kinase inhibitor with CNS activity that has shown efficacy in RET fusion-positive... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1261 |
| SubjectTerms | Adverse events Alanine Alanine Transaminase Aspartate aminotransferase Aspartate Aminotransferases Biomarkers Carcinoma, Non-Small-Cell Lung - drug therapy Disease Drug dosages Enzyme inhibitors FDA approval Health facilities Hematology, Oncology, and Palliative Medicine Humans Laboratories Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Medical research Non-small cell lung carcinoma Oncology Oral administration Patients Population Protein Kinase Inhibitors - adverse effects Proto-Oncogene Proteins c-ret - genetics Pyrazoles Pyridines Regulatory approval Response rates Safety Solid tumors Thyroid cancer Thyroid Neoplasms - drug therapy Thyroid Neoplasms - genetics Tumors |
| Title | Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1470204522005411 https://www.clinicalkey.es/playcontent/1-s2.0-S1470204522005411 https://dx.doi.org/10.1016/S1470-2045(22)00541-1 https://www.ncbi.nlm.nih.gov/pubmed/36108661 https://www.proquest.com/docview/2718121372 https://www.proquest.com/docview/2715443028 https://pubmed.ncbi.nlm.nih.gov/PMC11702314 |
| Volume | 23 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELdgkxAviO8VxnRIPGzSTGMnjV1eEJs6DcQGGp3Ut8hxHK2iSkqTIvW_40_jzkmzja_xUimNL4niy93vzuffMfbK6SCLpTY8S9OYR9YqnmYq5cPI6nSQBXqoab_zyWl8fB59mAwmbcKtassq1zbRG-qstJQj70tFvkiESr6df-PUNYpWV9sWGrfZJlGXUUmXmnQBl1BNCaOIVMCJdv1yB0__S_fnrpR7BFwEF3_zTb9jz19LKK_4pKP77F4LJuFdM_sP2C1XPGR3Ttrl8kfsx3iJkf2C-2o6HAOOCCOMXYEpMqhM7uoVlDlUbjZ3C0reFdMUpgW0bKsVUJoWzkZjyJeUVuNNjdd3B6iy0wxqf_0K_DYuoCw8zNB6QEkHq0V5Zcjux_cHeKHxJ46vbO8NGJhfoAcF0Zf7QD28OOqjm-0D-tWvrgbfTuQxOz8ajQ-PeduygVuMi2oe5kQ4r93A6UwYmYaRTSMTGKUJbeSoFkLldhhYmRq0NTaMDULQQYQBuh5isBQ-YRtFWbgtBtaHXqHWUZYhqhQGoU6E4V9ulXYqkz0WrScrsS2fObXVmCVd4RrNcUJznEiZ-DlORI-97sTmDaHHTQLxWhOS9W5VtK8JupybBNWfBF3VWokqEUmFoxtp6bntvShK6k6yBUINwPmfm26vlTXp7nP57fTYy-402hFaHDKFK5d-DFEhItzssaeNbnfvJ4ypH1dMz3VN67sBxFF-_UwxvfBc5dTYCEOI6Nm_n-s5uytpX4mvktxmG_Vi6V4g2qvTHf9J468-FDts82B0-vnsJ2AuTxg |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1tb9MwELZGJwFfEO8UBhwSSJs008ZJExcJIQadWtYWtHXSvoXEcbSKkpQmBfVP8Rv4adw5L9t4G1_2sc2dY-XOd8_Z5zvGnmrZjlwhAx6FocsdpTweRl7Iu46SYSdqy66k-86jsds_dN4ddY7W2PfqLgylVVY20RjqKFW0R94SHvkiy_bEq_kXTl2j6HS1aqFRqMWeXn3DkC17OXiL8n0mxG5v8qbPy64CXCF0z7kdU010qTtaRlYgQttRoRO0A0-SQ4xx5pYXq25biTDA5aBsN0CU1HEwhpRdxPM2jnuJrTs2hjINtr7TG3_Yr88tvCJp0nK8NqdC7yd3hloH9Z-bQmwRVLK49Tdv-Dva_TVp85QX3L3OrpXwFV4X-naDrenkJrs8Kg_ob7Efk-VnpOEmfw9pQFOJikCtIEgiyIJY5ytIY8j0bK4XtF2YTEOYJlDWd82ANoZhvzeBeEkbebzIKvuqARfJNILcjJ-BuTgGtO8PM7RXkNKP1SI9RbI5HOzgQJP3HD_Z1gsIYH6MPhusltgG6hrGcQXo2TagJ_-kczANTG6zwwsR5x3WSNJE32OgTLBnS-lEEeJYK0Bw5WDAGStPai8STeZUwvJVWUGdGnnM_DpVjmTsk4x9IXwjY99qsuc127woIXIeg1tpgl_dj0WL7qOTO4_R-xOjzkq7lPmWnyF1wS1MNX3Dipyy5iyhVwGp_uelG5Wy-vV7TlZrkz2pH6PlouOoINHp0tBQ8UUEuE12t9Dt-vvYLnUAc2leZ7S-JqCq6GefJNNjUx2dWilh0OLc__e8HrMr_clo6A8H470H7KqgWy0mR3ODNfLFUj9ErJmHj8oFDuzjRduUn03qiQo |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3ZbtNAcFWKVPGCuAkUGCSQWqnbxGvHu0FCCGijlh4gSKW8LfZ6rUYEO8QJKL_GE5_GzPpoy1Ve-ph4Zn3MvTsHY0-s6iShUBFP4jjkgTGSx4mMeS8wKu4mHdVTVO98cBjuHAVvht3hEvte18JQWmWtE52iTnJDe-RtIckWeb4U7bRKi3i31X8x-cJpghSdtNbjNEoW2bOLbxi-Fc93t5DWT4Xobw9e7_BqwgA36MbPuJ9Sf3Rlu1YlXiRiPzBxEHUiqcg4pvgWnkxNr2NEHKFoGD-M0GPqBhhPqh769j6ue4ldln7XIxmTwybY82SZPukFssOp5ftJ9VD7Q_PnmhDr5DR53PubXfzd7_01ffOUPexfY1crRxZelpx3nS3Z7AZbOaiO6m-yH4P5Z4ThLpMPYcBSs4rILCDKEiii1M4WkKdQ2PHETmnjMBvFMMqg6vRaAG0Rw_vtAaRz2tLjZX7ZVwsoLqMEZm79AlwJGdAJAIxRc0FOPxbT_BTI2v7uK1xo8JbjJ1t_BhFMjtF6g9cWG0DzwzjKgh1vANr0T3YGbpTJLXZ0IcS8zZazPLN3GRgX9vlKBUmCHq0XoZsVYOiZGqmsTESLBTWxtKl6qdNIj7FukuaIxpporIXQjsbaa7HNBm1SNhM5DyGsOUHXlbKo2zWau_MQ5Z8QbVFpqEJ7ukDoElu4vvoOFTFVg1k5YaVz9T83Xa2ZVTf3OZHbFnvcXEYdRgdTUWbzuYOhNozo6rbYnZK3m-_jhzQLLKTnOsP1DQD1Rz97JRsduz7pNFQJw5fg3r-f6xFbQU2i93cP9-6zK4LKW1yy5ipbnk3n9gE6nbP4oZNuYB8vWp38BIf6i9o |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tumour-agnostic+efficacy+and+safety+of+selpercatinib+in+patients+with+RET+fusion-positive+solid+tumours+other+than+lung+or+thyroid+tumours+%28LIBRETTO-001%29%3A+a+phase+1%2F2%2C+open-label%2C+basket+trial&rft.jtitle=The+lancet+oncology&rft.au=Subbiah%2C+Vivek%2C+MD&rft.au=Wolf%2C+J%C3%BCrgen%2C+Prof&rft.au=Konda%2C+Bhavana%2C+MD&rft.au=Kang%2C+Hyunseok%2C+MD&rft.date=2022-10-01&rft.issn=1470-2045&rft.volume=23&rft.issue=10&rft.spage=1261&rft.epage=1273&rft_id=info:doi/10.1016%2FS1470-2045%2822%2900541-1&rft.externalDBID=ECK1-s2.0-S1470204522005411&rft.externalDocID=1_s2_0_S1470204522005411 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14702045%2FS1470204522X00119%2Fcov150h.gif |